Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

- Venneti, Sriram, Kawakibi, Abed Rahman, Ramage, Samuel, Chi, Andrew, Wen, Patrick Y., Arrillaga-Romany, Isabel, Batchelor, Tracy T., Butowski, Nicholas A., Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca A., de Groot, John, Ji, Sunjong, Mehta, M, Hall, MD, Daghistani, D, Cloughesy, TF, Ellingson, BM, Beccaria, K, Varlet, P, Kim, MM, Umemura, Y, Garton, H, Waszak, Sebastian M., Franson, A, Schwartz, J, Jain, R, Kachman, M, Baum, H, Burant, CF, Mottl, SL, Cartaxo, RT, John, V, Messinger, D, Sweha, StefanR, Qin, T, Peterson, E, Sajjakulnukit, P, Ravi, K, Waugh, A, Walling, D, Ding, Y, Xia, Z, Schwendeman, A, Hawes, D, Mota, Mateus, Yang, F, Judkins, AR, Wahl, D, Lyssiotis, CA, de la Nava, D, Alonso, MM, Eze, A, Spitzer, J, Schmidt, SV, Duchatel, Ryan J., Pun, Matthew, Dun, Matthew D., Cain, JE, Jiang, L, Stopka, SA, Baquer, G, Regan, MS, Filbin, MG, Agar, NYR, Zhao, L, Kumar-Sinha, C, Deogharkar, Akash, Mody, R, Chinnaiyan, A, Kurokawa, R, Pratt, D, Yadav, VN, Grill, J, Kline, C, Mueller, S, Resnick, A, Nazarian, J, Chung, Chan, Allen, JE, Odia, Y, Gardner, SL, Koschmann, C, Tarapore, Rohinton S.

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies

- Findlay, Izac J., De Iuliis, Geoffry N., Duchatel, Ryan J., Jackson, Evangeline R., Vitanza, Nicholas A., Cain, Jason E., Waszak, Sebastian M., Dun, Matthew D.